



Zai Lab Announces Appointment of Harald Reinhart as Chief Medical Officer, Autoimmune and Infectious Diseases

May 24, 2017

Shanghai, China – 23 May 2017 – Zai Lab Ltd, a Shanghai-based biopharmaceutical company bringing transformative medicines to China and discovering and developing novel therapeutics for patients worldwide, announced today that Dr. Harald Reinhart has joined Zai Lab and will serve in a senior leadership role as Chief Medical Officer, Autoimmune and Infectious Diseases. Dr. Reinhart is a seasoned industry expert and will support the Company in the strategic development and expansion of their growing clinical pipeline focused on autoimmune and infectious diseases. He will report to Samantha Du, CEO of Zai Lab.

"We are delighted to welcome Harald to our management team at Zai Lab and look forward to adding his substantial insights and experience in pharmaceutical development in general and in the particular areas for which he'll be responsible," said Samantha Du, CEO of Zai Lab. "Harald has already greatly contributed to the Company in the past two years through his invaluable support as our advisor and his instrumental role in advancing and assisting Zai Lab's strategic pursuits within the realm of autoimmune and infectious diseases."

"I am enthusiastic about becoming a part of Zai Lab and contributing to their mission to provide novel therapies for the existing and expanding needs of patients in China and globally," said Harald Reinhart. "Samantha and her team have positioned the company for success and I am thrilled to further support them in the advancement of their pipeline."

Dr. Reinhart joins Zai Lab with over 25 years of experience in the pharmaceutical industry and an extensive background as a pharmaceutical executive. Most recently, he served as Managing Member of Allphase Pharma Consulting, LLC, a company he founded, where he advised a global clientele on topics such as strategic drug development and regulatory affairs and provided support for business development and licensing activities. Prior to that, Dr. Reinhart served as Senior Vice President and Head of Clinical Development & Medical Affairs (CD&MA) for the US branch of Shionogi. In that role, he provided medical oversight on the company's pharmaceutical pipeline at all stages of development in infectious diseases and other therapeutic areas. Dr. Reinhart also worked at Novartis for 8 years and Bayer for 12 years, moving up through a variety of roles and ending at Vice President and US-Section Head of Novartis. Harald trained and completed his residency as a medical doctor in Germany and later received board-certifications in Internal Medicine and Infectious Diseases in the United States at the Medical College of Pennsylvania, PA and Wayne State University, MI. He is currently Adjunct Clinical Professor of Infectious Diseases at Yale School of Medicine.

About Zai Lab

Zai Lab is a Shanghai-based innovative biopharmaceutical company. The company's globally- experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing novel therapeutics for patients worldwide. The vision at Zai Lab is to create a premier drug discovery, development, manufacturing and commercialization organization built on a foundation of world-class expertise and insights into the existing and expanding needs of Chinese patients. Zai Lab has a team of leaders who have a collective track record in all aspects of our business, including pioneering success in the regulatory process in China. The company has assembled a pipeline of potential best-in-class and first-in-class in China biopharmaceuticals at different stages of development by securing partnerships with leading multinational pharmaceutical and highly innovative biotechnology companies.

For more information, please visit www.zailaboratory.com.

Contacts:

Zai Lab
Vivian Tao
vtao@zailaboratory.com
+86 21 6163 2575